Quiescent phenotype of tumor-specific CD8+ T cells following immunization

Blood

Volumn 104, Issue 7, 2004, Pages 1970-1978

  Monsurrò, Vladia ^b   Wang, Ena ^b   Yamano, Yoshisha ^b   Migueles, Stephen A ^b   Panelli, Monica C ^b   Smith, Kina ^b   Nagorsen, Dirk ^b   Connors, Mark ^b   Jacobson, Steven ^b   Marincola, Francesco M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

209 2M PEPTIDE; CD8 ANTIGEN; COMPLEMENTARY DNA; COMPLEMENTARY RNA; EPITOPE; GLYCOPROTEIN GP 100; INTERLEUKIN 2; RNA; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; TAX PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CYTOTOXICITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNIZATION; MELANOMA; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 2442707309     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-02-0525     Document Type: Article

References (59)

1. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002;3:999-1005.
2. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Tumors as elusive targets of T cell-directed immunotherapy. Trends Immunol. 2003;24:334-341.
3. Lee K-H, Wang E, Nielsen M-B, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol. 1999;163:6292-6300.
4. Thurner B, Haendle I, Roder C, et al. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190:1669-1678.
5. Scheibenbogen C, Schmittel A, Keilholz U, et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother. 2000;23:275-281.
6. + T cells after vaccination with antigenic peptide. Clin Cancer Res. 2001;7:796s-803s.
7. Dunn GP, Bruce AT, Ikeda H, Old U, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-998.
8. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999;5:677-685.
9. Valmori D, Scheibenbogen C, Dutoit V, et al. Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res. 2002;62:1743-1750.
10. + effector alpha beta T cells. J Immunol. 2001;167:6165-6170.
11. + T cells. J Immunol. 2000;165:2287-2296.
12. Monsurrò V, Nielsen M-B, Perez-Diez A, et al. Kinetics of TCP use in response to repeated epitope-specific immunization. J Immunol. 2001;166:5817-5825.
13. Pittet MJ, Zippelius A, Speiser DE, et al. Ex vivo IFN-γ secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol. 2001;166:7634-7640.
14. Appay V, Nixon DF, Donahoe SM, et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med. 2000;192:63-75.
15. + T cells. J Exp Med. 1997;186:1407-1418.
16. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:659-660.
17. Champagne P, Ogg GS, King A, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 2001;410:106-111.
18. + T cells. J Immunol. 2002;168:5933-5942.
19. + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol. 2002;3:1061-1068.
20. + T-cell maturation: CD27 might provide a clue. Trends Immunol. 2002;23:586-591.
21. + T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8:379-385.
22. Speiser DE, Lienard D, Pittet MJ, et al. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol. 2002;32:731-741.
23. Tan LC, Gudgeon N, Annels NE, et al. A re-evaluation of the frequency of CD8(+) T cells specific for EBV in healthy virus carriers. J Immunol. 1999;162:1827-1835.
24. Rooney CM, Roskrow MA, Smith CA, Brenner MK, Heslop HE. Immunotherapy of Epstein-Barr virus-associated cancer. J Natl Cancer Inst Monogr. 1998;23:89-93.
25. Haque T, Taylor C, Wilkie GM, et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation. 2001;72:1399-1402.
26. + cells in HTLV type 1-associated myelopathy/tropical spastic paraparesis: correlation with HTLV type 1 proviral load. AIDS Res Hum Retroviruses. 2000;16:1705-1709.
27. Yamano Y, Nagai M, Brennan M, et al. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood. 2002;99:88-94.
28. + T cells. Blood. 2001;95:1506-1511.
29. + T-cell epitopes by acquisition of peptide-HLA-GFP complexes: analysis of T-cell phenotype and function in chronic viral infections. Nat Med. 2003;9:469-476.
30. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201 binding residues. J Immunol. 1996;157:2539-2548.
31. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 1996;56:4749-4757.
32. Wang E, Miller L, Ohnmacht GA, Liu E, Marincola FM. High fidelity mRNA amplification for gene profiling using cDNA microarrays. Nat Biotech. 2000;17:457-459.
33. Cormier JN, Hijazi YM, Abati A, et al. Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo. Int J Cancer. 1998;75:517-524.
34. Wang E, Miller LD, Ohnmacht GA, et al. Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 2002;62:3581-3586.
35. Panelli MC, Wang E, Phan G, et al. Genetic profiling of peripharal mononuclear cells and melanoma metastases in response to systemic interleukin-2 administration. Genome Biol. 2002;3: RESEARCH0035.
36. Wang E, Marincola FM. Amplification of small quantities of mRNA for transcript analysis. In: Bowtell D, Sambrook J, eds. DNA arrays-A Molecular Cloning Manual. Cold Springs Harbor, NY: Cold Spring Harbor Laboratory Press; 2002:204-213.
37. Feldman AL, Costouros NG, Wang E, et al. Advantages of mRNA amplification for microarray analysis. Biotechniques. 2002;33:906-914.
38. Ross DT, Schert U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000;24:227-235.
39. Rosenberg SA, Yang JC, Schwartzentruber D, et al. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321-327.
40. Kaech SM, Hemby S, Kersh E, Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell. 2002;111:837-851.
41. Saimura M, Nagai E, Mizumoto K, et al. Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4. Clin Cancer Res. 2002;8:3243-3249.
42. Andersson M, Gunne H, Agerberth B, et al. NK-lysin, a novel effector peptide of cytotoxic T and NK cells. Structure and cDNA cloning of the porcine form, induction by interleukin 2, antibacterial and antitumor activity. EMBO J. 1995;14:1615-1625.
43. Medley GQ, Kedersha N, O'Brien S, et al. Characterization of GMP-17, a granule membrane protein that moves to the plasma membrane of natural killer cells following target cell recognition. Proc Natl Acad Sci U S A. 1996;93:685-689.
44. Wex T, Buhling F, Wex H, et al. Human cathepsin W, a cysteine protease predominantly expressed in NK cells, is mainly localized in the endoplasmic reticulum. J Immunol. 2001;167:2172-2178.
45. Lima M, Almeida J, dos Anjos Teixeira M, Queiros ML, Justica B, Orfao A. The "ex vivo" patterns of CD2/CD7, CD57/CD11c, CD38/CD11b, CD45RO/CD45RA, and CD11a/HLADR expression identify acute/early and chronic/late NK-cell activation states. Blood Cells Mol Dis. 2002;28:181-190.
46. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Immunol. 2003;3:269-279.
47. Kitchen SG, LaForge S, Patel VP, Kitchen CM, Miceli MC, Zack JA. Activation of CDB T cells induces expression of CD4, which functions as a chemotactic receptor. Blood. 2002;99:207-212.
48. Sarwal M, Chang S, Barry C, Alizadeh AA, Salvatierra O, Brown PO. Genomic analysis of renal allograft dysfunction using cDNA microarrays. Transplant Proc. 2001;33:297-298.
49. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1998;17:2105-2116.
50. Marincola FM, Jaffe EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol. 2000;74:181-273.
51. - cells are induced by antigen and evolve through extensive rounds of division. Int Immunol. 1999;11:1027-1033.
52. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003;4:225-234.
53. Rubio V, Stuge TB, Singh N, et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med. 2003;9:1377-1382.
54. + T cell memory: relationship between epitope specificity, cell phenotype and immediate effector function. J Immunol. 2001;167:2019-2029.
55. Zinkernagel RM. The role of antigen in maintaining T cell memory. Dev Biol Stand. 1994;82:189-191.
56. + T-cell approach feasible? Nat Immunol. 2002;2:283-291.
57. DePaola F, Ridolfi R, Riccobon A, et al. Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2. Br J Cancer. 2003;88:320-326.
58. Sarwal M, Chang S, Barry C, Alizadeh AA, Salvatierra O, Brown PO. Genomic analysis of renal allograft dysfunction using cDNA microarrays. Transplant Proc. 2001;33:297-298.
59. Blattman JN, Grayson JM, Wherry EJ, Kaech SM, Smith SM, Ahmed R. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med. 2003;9:540-547.